XML 33 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Risk Management (Tables)
3 Months Ended
Sep. 30, 2022
Disclosure Of Financial Risk Management [Abstract]  
Schedule of Deposits Held which Derive Interest Revenue with Maximum and Minimum Interest Rates Being Earned

 

 

 

As of

 

 

As of

 

 

 

September 30, 2022

 

 

June 30, 2022

 

(in U.S. dollars, in thousands, except percent data)

 

Low

 

 

High

 

 

US$

 

 

Low

 

 

High

 

 

US$

 

Funds invested – US$

 

 

0.05

%

 

 

0.05

%

 

 

61,438

 

 

0.00%(1)

 

 

0.00%(1)

 

 

 

49,383

 

Rate increase by 10%

 

 

0.06

%

 

 

0.06

%

 

 

34

 

 

0.03%(1)

 

 

0.03%(1)

 

 

 

15

 

Rate decrease by 10%

 

 

0.05

%

 

 

0.05

%

 

 

(28

)

 

0.03%(1)

 

 

0.03%(1)

 

 

 

(15

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in Australian dollars, in thousands, except percent data)

 

Low

 

 

High

 

 

A$

 

 

Low

 

 

High

 

 

A$

 

Funds invested – A$

 

 

2.84

%

 

 

2.84

%

 

 

600

 

 

 

1.50

%

 

 

1.50

%

 

 

600

 

Rate increase by 10%

 

 

3.12

%

 

 

3.12

%

 

 

2

 

 

 

1.65

%

 

 

1.65

%

 

 

1

 

Rate decrease by 10%

 

 

2.56

%

 

 

2.56

%

 

 

(2

)

 

 

1.35

%

 

 

1.35

%

 

 

(1

)

 

(1)

The interest rate was 0% for the period ended June 30, 2022. The sensitivity assumes the interest rate to increase or decrease by 0.03%, which is consistent with prior periods.

Summary of Borrowing to Price Rate Changes

The exposure of the Group’s borrowing to price rate changes are as follows:

 

 

 

As of

 

 

As of

 

 

 

September 30, 2022

 

 

June 30, 2022

 

(in U.S. dollars, in thousands, except percent data)

 

Total

 

 

% of total loans

 

 

Total

 

 

% of total loans

 

Financial liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current borrowings

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Borrowings - NovaQuest

 

 

816

 

 

 

1

%

 

 

372

 

 

 

0

%

Non-current borrowings

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Borrowings - NovaQuest

 

 

49,511

 

 

 

50

%

 

 

47,898

 

 

 

50

%

 

 

 

50,327

 

 

 

51

%

 

 

48,270

 

 

 

50

%

 

Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value

As of September 30, 2022, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis is as follows:

 

(in U.S. dollars, in thousands)

 

Within

1 year

 

 

Between

1-2 years

 

 

Between

2-5 years

 

 

Over

5 years

 

 

Total

contractual

cash flows

 

 

Carrying

amount

 

Borrowings(1)(2)

 

 

(6,161

)

 

 

(13,290

)

 

 

(155,120

)

 

 

 

 

 

(174,571

)

 

 

(99,675

)

Trade payables

 

 

(17,663

)

 

 

 

 

 

 

 

 

 

 

 

(17,663

)

 

 

(17,663

)

Lease liabilities

 

 

(4,074

)

 

 

(4,443

)

 

 

(2,272

)

 

 

 

 

 

(10,789

)

 

 

(9,957

)

Contingent consideration(3)

 

 

(3,973

)

 

 

(2,115

)

 

 

(5,139

)

 

 

 

 

 

(11,227

)

 

 

(3,851

)

 

 

 

(31,871

)

 

 

(19,848

)

 

 

(162,531

)

 

 

 

 

 

(214,250

)

 

 

(131,146

)

 

(1)

Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at September 30, 2022 without taking into account drawdowns of further tranches.

(2)

In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD.

(3)

In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. The carrying amount reflects the discounted and probability adjusted contractual balance. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments.